TABLE 5.
Vaccine | A/H1N1
|
A/H3N2
|
B
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 6
|
Day 13
|
Day 6
|
Day 13
|
Day 6
|
Day 13
|
|||||||
na | MFRb (95% CI) | n | MFR (95% CI) | n | MFR (95% CI) | n | MFR (95% CI) | n | MFR (95% CI) | n | MFR (95% CI) | |
CAIV-T 107 | 8 | 7.15 (1.00, 303.0) | 5 | 55.0 (37.0, 227.0) | 7 | 1.00 (1.00, 30.0) | 4 | 36.5 (3.94, 193.0) | 6 | 3.00 (1.00, 20.0) | 4 | 73.5 (1.00, 237.0) |
CAIV-T <105 | 7 | 1.00 (1.00, 1.18) | 10 | 1.00 (1.00, 1.00) | 7 | 1.00 (0.67, 1.00) | 7 | 1.00 (1.00, 1.00) | 3 | 1.00 (1.00, 10.0) | 4 | 1.00 (1.00, 7.00) |
TIV | 7 | 1.00 (1.00, 29.0) | 9 | 3.00 (1.00, 5.67) | 6 | 2.00 (1.00, 3.00) | 6 | 2.50 (1.00, 41.3) | 2 | 1.00 (1.00, 1.00) | 2 | 1.00 (1.00, 1.00) |
Placebo | 6 | 1.00 (1.00, 1.00) | 6 | 1.00 (0.50, 1.00) | 6 | 1.00 (1.00, 1.00) | 4 | 1.00 (1.00, 1.00) | 3 | 1.00 (0.08, 1.00) | 3 | 1.00 (1.00, 1.00) |
Number of subjects in the analysis. This number was largely dependent on the number of subjects with sufficient blood volume drawn to enable the conduct of the assay.
MFR, median fold rise in the postvaccination compared with the prevaccination sample.